Ads
related to: biogen's biibthorne.com has been visited by 10K+ users in the past month
Search results
RBC maintains $317 price target on Biogen stock, cites Skyclarys importance By Investing.com
Investing.com· 17 hours agoOn Wednesday, RBC (TSX:RY) Capital maintained its Outperform rating on Biogen (NASDAQ:BIIB) shares...
Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?
Simply Wall St. via Yahoo Finance· 2 days agoIt is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock...
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with...
CBS 47 Fresno· 6 days ago("Biogen Inc." or "the Company") (NASDAQ: BIIB) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal ...
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks via Yahoo Finance· 7 days agoBiogen BIIB entered into a definitive agreement to acquire private biotech, HI-Bio, for a $1.15...
Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?
Zacks via Yahoo Finance· 6 days agoA month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have added about...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 5 days ago(“Biogen” or the “Company”) (NASDAQ: BIIB) in the United States District Court for the District of Colorado on behalf of all persons and entities who purchased or otherwise ...
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks via Yahoo Finance· 7 days agoThe acquisition will add Human Immunology Biosciences’ lead candidate, felzartamab, to Biogen’s...
Biogen's new acquisition target reveals 'provocative' trial results - Boston Business Journal
The Business Journals· 2 days agoJust days after Biogen Inc. announced it was buying Human Immunology Biosciences (HI-Bio) for $1.15...
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB...
Morningstar· 7 days ago(“Biogen” or the “Company”) (NASDAQ: BIIB) between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”). The Complaint further alleges that on November 8 ...
Needham & Company LLC Reiterates “Buy” Rating for Biogen (NASDAQ:BIIB)
ETF DAILY NEWS· 6 days agoBiogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “buy” rating restated by Needham & Company LLC in a report issued on Wednesday, Benzinga reports. Needham & Company ...